Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus ...

Core Insights - Corvus Pharmaceuticals announced additional data from its Phase 1/1b clinical trial of soquelitinib for T cell lymphoma, showcasing strong anti-tumor activity and encouraging results compared to standard treatments [1][2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a new immunotherapy approach for various cancers and immune diseases [10] - The lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [10] Clinical Trial Data - The Phase 1/1b trial enrolled 25 patients, with 23 evaluable patients showing a 39% objective response rate, including a 26% complete response rate [4][6] - The median duration of response was 17.2 months, with a median progression-free survival (PFS) of 6.2 months and an 18-month PFS rate of 30%, significantly better than the <20% rate for standard treatments [6] - Soquelitinib was well-tolerated, with no new safety signals or dose reductions reported [6] Future Trials - A registrational Phase 3 trial is underway for soquelitinib in patients with relapsed Peripheral T cell lymphoma (PTCL), aiming to enroll 150 patients [4] - The trial will compare soquelitinib against physician's choice of either belinostat or pralatrexate, with the primary endpoint being PFS [4] Mechanism of Action - Soquelitinib is designed to selectively inhibit ITK, which plays a crucial role in T cell immune function, potentially enhancing anti-tumor immunity by reducing T cell exhaustion [9] - The drug has shown the ability to shift T cell differentiation towards Th1 helper cells, which are essential for tumor immunity [9] Industry Context - Peripheral T cell lymphoma (PTCL) accounts for about 10% of non-Hodgkin's lymphomas in Western populations, with a high relapse rate and poor outcomes for patients [7] - There are currently no FDA-approved treatments for relapsed PTCL based on randomized trials, highlighting a significant unmet medical need [4][7]

Core Viewpoint - Corvus Pharmaceuticals is actively engaging with investors through one-on-one meetings and a fireside chat at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, scheduled for March 27, 2025 [1]. Group 1 - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various cancer and immune diseases [3]. - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3]. - Corvus has additional clinical-stage candidates aimed at treating a variety of cancer indications [3]. Group 2 - A live webcast of the fireside chat will be available, along with access for 90 days post-event, through the investor relations section of the Corvus website [2].

Core Viewpoint - Corvus Pharmaceuticals, Inc. will host a conference call and webcast on March 25, 2025, to provide a business update and report its fourth quarter and full year 2024 financial results [1]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel approach to immunotherapy for various cancer and immune diseases [3]. - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3]. - Corvus is also developing other clinical-stage candidates targeting a range of cancer indications [3]. Conference Call Details - The conference call can be accessed by dialing 1-800-717-1738 for domestic calls or 1-646-307-1865 for international calls, or through a provided link for instant access [2]. - A live webcast will be available via the investor relations section of the Corvus website, with a replay accessible for 90 days [2].

Core Insights - Corvus Pharmaceuticals has announced a Phase 2 clinical trial for soquelitinib, targeting autoimmune lymphoproliferative syndrome (ALPS), in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) [1][2] - The trial aims to evaluate the efficacy of ITK inhibition in improving immune system balance and reducing dysfunctional T cell accumulation in patients with ALPS [2][3] - Soquelitinib is also under investigation for other indications, including peripheral T cell lymphoma (PTCL) and atopic dermatitis, highlighting its potential versatility in treating various immune-related conditions [4][8] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for cancer and immune diseases [8] - The company's lead product candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit ITK, which plays a crucial role in T cell function [7][8] - Corvus is advancing soquelitinib through multiple clinical trials, including a registrational Phase 3 trial for PTCL and a Phase 1 trial for atopic dermatitis, with plans to initiate a Phase 1 trial for solid tumors in Q2 2025 [4][8] Disease Context - ALPS is a rare genetic disorder characterized by immune dysregulation, leading to symptoms such as lymphadenopathy, splenomegaly, and cytopenias, primarily caused by mutations in the Fas gene [5][6] - The condition typically manifests in early childhood and can lead to serious health complications, including autoimmune diseases and lymphoma, with no current cure available [2][5] - Current management strategies for ALPS involve empirical treatments aimed at alleviating symptoms and managing complications, including the use of corticosteroids and immunosuppressive medications [2][6]

Core Insights - Corvus Pharmaceuticals, Inc. is set to present a corporate overview and conduct one-on-one meetings with investors at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 [1] - The presentation will be available via a live webcast, which can be accessed for 90 days post-event through the investor relations section of the Corvus website [2] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [3] - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK, with additional clinical-stage candidates targeting multiple cancer indications [3]

Core Insights - Corvus Pharmaceuticals announced new interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, showing a favorable safety and efficacy profile compared to placebo [1][2][3] Efficacy Data - In Cohort 1, 26% of patients receiving soquelitinib achieved IGA 0 or 1, and 37% achieved EASI 75, while none in the placebo group reached these endpoints after four weeks [3][4] - The trial included 16 patients in Cohort 1 and 10 patients in Cohort 2, with the latter showing improved results with a 200 mg once daily dose compared to the initial cohort [2][3] Safety Profile - No significant safety issues or clinically significant laboratory abnormalities were reported, with all patients in Cohort 2 completing the 28-day treatment [4] Trial Design - The Phase 1 trial is randomized, double-blind, and placebo-controlled, planned to enroll 64 patients with moderate to severe atopic dermatitis who have failed prior therapies [7] - The trial examines multiple dosing regimens, including 100 mg twice daily and 200 mg once daily, with a total of four cohorts [7][8] Future Outlook - The company plans to report full results from all cohorts in the second quarter of 2025 and is also advancing a Phase 3 trial for relapsed peripheral T cell lymphoma [2][4]

Core Viewpoint - Corvus Pharmaceuticals, Inc. will present a corporate overview and conduct one-on-one meetings with investors at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025 [1]. Group 1: Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition as a novel immunotherapy approach for various cancers and immune diseases [3]. - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3]. - Corvus is developing other clinical-stage candidates targeting a range of cancer indications [3]. Group 2: Event Details - Richard A. Miller, M.D., the president and CEO of Corvus Pharmaceuticals, will present on January 15 at 2:15 pm ET / 11:15 am PT [1]. - An audio webcast of the presentation will be available live and for 30 days post-event, accessible via the investor relations section of the Corvus website [2].

Group 1 - Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported positive results from its phase 1 study using soquelitinib [CPI-818] for the treatment of atopic dermatitis [AD] [2] - The study is still in early stages, indicating potential for future developments in the treatment of AD [2] - The article highlights the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and a model portfolio of small and mid-cap stocks [2] Group 2 - The author of the article is Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace [1] - The service offers a two-week free trial and a subscription model priced at $49 per month or $399 per year with a discount for annual sign-ups [1] - The article does not contain any stock positions or plans to initiate positions in the companies mentioned [3]

Core Insights - Corvus Pharmaceuticals announced interim data from a Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, showing a favorable safety and efficacy profile [1][2][4] - The company reported cash proceeds of approximately $12.7 million from the early exercise of common stock warrants [1][18] Clinical Trial Overview - The Phase 1 trial is randomized, double-blind, and placebo-controlled, enrolling 64 patients who have previously failed one prior therapy [2][4] - Patients are assigned to one of four dosing cohorts, with doses including 100 mg twice daily, 200 mg once daily, 200 mg twice daily, and 400 mg once daily [2][3] Efficacy Results - In Cohort 1, the mean EASI score reduction at 28 days was 55.9% for soquelitinib compared to 27.0% for placebo, and at 58 days, it was 69.1% for soquelitinib versus 19.1% for placebo [9][10] - At day 28, 75% of soquelitinib patients achieved EASI 50, while no placebo patients achieved EASI 75 or EASI 90 [9][10] - The treatment effect began early, with improvements noted as soon as eight days into the treatment [9] Safety Profile - No significant safety issues were reported, with only two patients in the soquelitinib group experiencing mild adverse events [13][15] - All patients completed the 28-day dosing period without serious adverse events [13][15] Cytokine Analysis - The trial observed reductions in cytokines IL-5, IL-17, IL-31, IL-33, and TSLP, correlating with clinical improvement in EASI scores [16] - No such relationships were observed in the placebo group, indicating a potential mechanism of action for soquelitinib [16] Ongoing Development - The company is looking forward to completing the Phase 1 trial and initiating further trials for soquelitinib in other immune diseases [2][4] - Initial results from Cohort 2, which includes patients receiving 200 mg once daily, are consistent with those from Cohort 1, with no significant adverse events reported [17] Company Background - Corvus Pharmaceuticals is focused on developing ITK inhibition as a novel approach to treat various cancers and immune diseases, with soquelitinib as its lead candidate [23]